MedTrace Logo

Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement

NCT06033599 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2026-04-28

No results posted yet for this study

Summary

The purpose of this study is to 1) examine barriers and facilitators to implementation of MI and MORE for polysubstance use and evaluate strategies for optimizing training, fidelity, and clinic uptake, and 2) evaluate patient outcomes related to the effectiveness of MORE decreasing opioid, tobacco, and other drug use.

Conditions

  • Polysubstance Abuse
  • Opioid Use
  • Tobacco Use

Interventions

OTHER

MORE and MI and NRT

Eight group Mindfulness Oriented Recovery Enhancement sessions and one motivational interviewing session and nicotine replacement therapy.

OTHER

MORE and No MI and NRT

Eight group Mindfulness Oriented Recovery Enhancement sessions and nicotine replacement therapy.

OTHER

Support Group and MI and NRT

Eight group support group sessions and one motivational interviewing session and nicotine replacement therapy.

OTHER

Support Group and No MI and NRT

Eight group support group sessions and and nicotine replacement therapy.

Sponsors & Collaborators

  • University of Utah

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Rutgers, The State University of New Jersey

    lead OTHER

Principal Investigators

  • Nina Cooperman, PsyD · Rutgers Robert Wood Johnson Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-05
Primary Completion
2027-06-30
Completion
2028-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06033599 on ClinicalTrials.gov